Skip to content
RDL Network logo
Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma — Adnan Khattak (2018) | RDL Network